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Abstract
Programmed cell death ligands (PD-Ls) are expressed in tumor cells where they bind 
to programmed cell death-1, an immunocyte co–receptor, resulting in tumor cell eva-
sion from the immune system. Chemotherapeutic drugs have been recently reported 
to induce the expression of PD-L, such as PD-L1, in some cancer cells. However, 
little is known regarding PD-L2 expression and its role in oral squamous cell carci-
noma (OSCC). In this study, we examined the effect of cisplatin on the expression 
and regulation of PD-L2 in OSCC cell lines and analyzed malignant behavior in PD-
L2-expressing cells using colony, transwell and transformation assays. In addition, we 
examined PD-L2 expression in the tumor tissues of OSCC patients using cytology 
and tissue microarray methods. In OSCC cell lines, cisplatin treatment upregulated 
PD-L2 expression, along with that of the drug efflux transporter ABCG2, via signal 
transducers and activator of transcription (STAT) 1/3 activation. Moreover, PD-L2-
positive or PD-L2-overexpressing cells demonstrated upregulation in both invasion 
and transformation ability but not in proliferation compared with PD-L2-negative or 
PD-L2-silencing cells. PD-L2 expression was also observed in OSCC cells of cytol-
ogy samples and tissue from OSCC patients. The intensity of PD-L2 expression was 
correlated with more malignant morphological features in the histological appear-
ance and an invasive pattern. Our findings indicate that cisplatin-upregulated PD-L2 
expression in OSCC via STAT1/3 activation and the expression of PD-L2 are likely to 
be associated with malignancy in OSCC. The PD-L2 expression in cisplatin-resistant 
OSCC cells may be a critical factor in prognosis of advanced OSCC patients.
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1  | INTRODUC TION
Programmed cell death (PD)-1 is an immune co–receptor that has 
been well characterized as a negative regulatory molecule of immu-
nocytes at immune checkpoints. PD-1 ligands belong to the B7 fam-
ily of molecules and include PD-L1 (B7-H1) and PD-L2 (B7-DC).1,2 
PD-L1 is widely expressed in a variety of immunocytes, including T 
cells, B cells, regulatory T cells, natural killer T cells, dendritic cells 
(DC) and tumor cells.3,4 In tumor cells, PD-L1 binds to PD-1 on T cells 
and suppresses their immune function, which leads to the promotion 
of tumor growth, metastasis and cachexia.5 Indeed, immunotherapy 
using anti–PD-1 antibodies has been reported to prevent immune 
tumor evasion from the immune system in patients with various 
solid malignancies, allowing immunocytes to appropriately attack 
the tumor cells.6
Programmed cell death-2 is expressed in antigen-presenting 
cells, including DC, macrophages, B cells and tumor cells.7,8 Like PD-
L1, PD-L2 has been reported to bind to PD-1, resulting in the evasion 
of tumor cells from the immune system.9,10
It has recently been revealed that the distribution of pro-
grammed cell death ligands (PD-L) differs depending on the type 
of head and neck squamous cell carcinoma (HNSCC).11,12 In HNSCC 
patients, PD-L2 expression has been reported to be greater than 
that of PD-L1.13 In addition, PD-1/PD-L2 interactions have been re-
ported to have different association/dissociation kinetics, exhibiting 
a 2-6-fold higher affinity compared with PD-1/PD-L1 interactions.14 
However, it remains unclear whether PD-L2 expression and the ratio 
of PD-L2/PD-L1 expression play an important role in HNSCC.
Squamous cell carcinomas (SCC) comprise over 95% of malignant 
tumors in the head and neck region, including the oral cavity. Oral 
squamous cell carcinoma (OSCC) is the most common malignancy of 
the maxillofacial region, accounting for nearly 3% of all cancer cases 
worldwide.15 OSCC severely impairs patient quality of life because 
of the associated damage to speech, swallowing and mastication. 
However, the survival of patients with metastatic OSCC has signifi-
cantly improved with treatments involving platinum-based salt drugs 
and, more recently, immune checkpoint targeting therapies. Indeed, 
the inhibition of PD-1/PD-L1 binding using anti–PD-1 antibodies 
has been reported to result in increased disease control and sur-
vival rates as compared with conventional chemotherapy alone.16,17 
Despite these therapeutic advances, the mortality of OSCC patient 
remains high due to the development of distant metastases and local 
and systemic recurrences, which are resistant to both chemotherapy 
and radiotherapy.18
Several studies have evaluated the ability of chemotherapy, in-
cluding anti–tumor drugs such as cisplatin, to modulate tumor immu-
nogenicity and to influence adaptive immunity.19 From these studies, 
it has recently been reported that cisplatin induces the expression 
of PD-L1 in bladder cancer and non–small cell lung cancer.20,21 
However, the expression and regulatory mechanisms of PD-L2 have 
not been evaluated in OSCC.
Therefore, in the present study, we evaluated the effect of cis-
platin on the expression of PD-L2 in OSCC cell lines. In addition, 
we evaluated whether PD-L2 expression was involved in the malig-
nancies observed in cisplatin-resistant OSCC cell lines. Furthermore, 
PD-L2 expression in the tumor tissues from OSCC patients was de-
termined using cytology and tissue microarray methods.
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
This study was approved by the Ethics Review Board of Fukuoka 
Dental College (approval number: 432). All studies involving human 
participants were conducted in full compliance with the Declaration 
of Helsinki. All participants completed an informed consent form.
2.2 | Cell culture
Human oral squamous carcinoma cells HSC-2 and HSC-3 were ob-
tained from the Cell Resource Center, Institute of Developmental, 
Aging and Cancer, Tohoku University (Sendai, Japan). Cells were 
seeded at a density of 1 × 105 cells/mL and cultured at 37°C in a 
humidified atmosphere of 95% air and 5% CO2 in DMEM (Wako) 
supplemented with 10% FBS (Sigma-Aldrich). Upon reaching sub-
confluence, cells were incubated in culture medium with or with-
out cisplatin [cis-Diammineplatinum(II)] dichloride (1-5 μmol/L); 
Sigma-Aldrich) for 0-72 hours. In some experiments, the cells were 
incubated in culture medium containing cisplatin and fludarabine 
(10 μmol/L; STAT1 inhibitor; Sigma-Aldrich) or cryptotanshinone 
(10 μmol/L; STAT3 inhibitor; Sigma-Aldrich).
2.3 | Cellular proliferation assay
Cellular proliferation was measured by using a Cell Counting Kit-8 
solution (CCK-8; Dojindo Laboratories). Briefly, the cells were seeded 
in 96-well plates at a density of 1000 cells/well in 100 μL D-MEM. At 
0, 24, 48 or 72 hour after cisplatin treatment, 10 μL of CCK8 reagent 
was added to each well and the plates were incubated at 37°C for 
1 hour. Absorbance was read at 450 nm using a microplate reader 
(Mode 680; Bio-Rad). Culture solution containing CCK-8 reagent but 
without cells was used as a blank control.
2.4 | RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cells using TRIzol Reagent. First-
strand cDNA was synthesized from 3 μg of total RNA using SuperScript 
II reverse transcriptase (Invitrogen, Thermo Fisher Scientific). To detect 
mRNA expression, we selected gene-specific primers based on the nu-
cleotide sequence of the cDNA. QRT-PCR analyses of the targeted 
mRNA were performed using the SYBR Prime Script RT-PCR Kit with 
an ABI 7500 Real-Time PCR System (Applied Biosystems). Reaction 
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conditions were as follows: an initial step at 95°C for 30 seconds, fol-
lowed by 40 cycles of denaturation at 95°C for 5 seconds, annealing 
at 60°C for 10 seconds, and extension at 72°C for 35 seconds. β-actin 
was used as an internal standard to control for amplification variabil-
ity due to differences in starting mRNA concentrations. The threshold 
cycle (Ct) was defined as the fractional cycle number. The gene expres-
sion level was expressed relative to that of β-actin and the delta (delta 
Ct) method was used to calculate the fold change for each sample.
2.5 | Western blot analysis
Cells were lysed in TNT buffer (Roche). Protein content was meas-
ured with a protein assay kit (Thermo Scientific). Briefly, 20 µg of 
each protein was subjected to 10.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis. Separated proteins were then elec-
trophoretically transferred to PVDF membranes at 75 V for 1.5 hour 
at 4°C. The membranes were then incubated overnight with anti-
bodies against the target molecules in a 5% skimmed milk solution 
at 4°C (Table S1). Blots were then washed in TBST (10 mmol/L tris–
HCl, 50 mmol/L, NaCl 0.25% Tween-20), incubated for 1 hour with 
HRP-conjugated anti–rabbit or mouse IgG secondary antibodies, 
and developed using an enhanced chemiluminescence system (GE 
Healthcare). In some experiments, cellular total proteins were iso-
lated as the membrane and cytoplasm fractions using the Mem-PER 
Plus Membrane Protein Extraction Kit (Thermo Scientific). Briefly, 
cells were washed with wash buffer, and 0.75 mL of permeabilization 
buffer containing protease inhibitors was added. Cell suspensions 
were centrifuged at 16 000 g for 15 minutes at 4°C; the collected 
supernatant contained the cytosolic proteins. Membrane-enriched 
pellets were incubated for 30 minutes with solubilization buffer and 
centrifuged at the same condition; the collected supernatant con-
tained the membrane fraction.
2.6 | Flow cytometry analysis and cell sorting
Cells were washed twice with PBS after treatment with Fc Receptor 
Blocking Solution (Human TruStain FcX; BioLegend) and incubated 
with the cell surface antigen of PD-L2 (CD273) conjugated with phy-
coerythrin (PE, BioLegend) or ABCG2 (CD338) conjugated with PE-
Cy5 (BioLegend). The labeled cells were analyzed by flow cytometry 
analysis using the On-chip system (On-chip Biotechnologies). The 
ratio of each antibody-positive cell to the total cells was quantified 
using the associated analysis software. In some experiments, PD-L2-
positive or negative cells were sorted and collected using fluores-
cence-activated cell sorting.
2.7 | Colony assay
Cells were seeded at a low density of 1 × 103 cells/mL and cultured 
at 37°C in 100-mm culture dishes. After 10 and 13 days, the colonies 
that were forming were stained with crystal biored and stained colo-
nies were counted.
2.8 | Transwell invasion assays
Cells were seeded onto 24-well plates (6.5-mm diameter; 8-μm pore 
size chamber inserts; Corning, USA) for cell invasion assays. Briefly, 
cells were added to the upper collagen-coated chamber of the tran-
swell insert (1 × 103 cells/well). After 24 and 48 hours of incuba-
tion, the cells that remained at the top of the inserts were removed. 
Invasive cells that were present on the lower surface of the inserts 
were fixed with methanol and stained with calcein-AM (Dojindo) for 
15 minutes. The number of invasive cells was counted under a fluo-
rescent microscope. Data were expressed as the average number of 
cells/transwell ± SD.
2.9 | Transformation assay
Transforming assays were performed using Cytoselect 96-well trans-
forming plates in conjunction with a Soft Agar Colony Formation Kit 
(Cell Biolabs). Briefly, cell suspensions at a density of 1 × 104 cells/
mL were mixed with an agar solution. The culture medium contain-
ing the mixed cell suspension was then incubated in 96-well plates 
(100 μL/well) for 10 days at 37°C and 5% CO2. The formation of cell 
colonies was examined using a light microscope. After removal of 
the culture medium, lysis buffer was added to the wells, which were 
incubated for 15 minutes. The fluorescence at 520 nm excited at 480 
nm was measued for colony formation in the agar floating culture 
using a microplate reader (Mode 680; Bio-Rad).
2.10 | Immunochemistry
Immunohistochemistry was performed for tissue microarray sec-
tions (Cat. No. OR208 US Biomax) using the Histofine Simple Stain 
MAX-PO(R) kit (Nichirei). Briefly, antigen retrieval was performed 
by autoclave treatment and endogenous peroxidase activity was 
blocked by treatment with H2O2. Following incubation with anti–
human PD-L2 antibody (Cell Signaling Technology) then a secondary 
antibody (Nichirei), the tissue microarray sections were visualized 
using a DAB substrate kit (Nichirei), before counterstaining with he-
matoxylin. As a negative control, staining was performed without 
any primary antibody. The tissue microarray sections were indepen-
dently examined by two researchers, including a pathologist. The 
PD-L2 staining intensity of each tumor cell was classified into four 
levels relative to that of infiltrating macrophages as internal control 
in the same section (Figure S1): negative, no specific staining; low, 
weakly stained tumor cell; intermediate, moderately stained tumor 
cell; and high, strongly stained tumor cells. The histological grading 
(differentiation degree) and Yamamoto-Kohama (YK)-classification 
(invasive pattern) were also determined and the invasive pattern 
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was categorized into three types: expansive type (YK-1 and 2), inter-
mediate type (YK-3) and invasive type (YK-4C and -4D). As for dif-
ferentiation degree, we evaluated the morphological features in the 
observed tissue microarray spots rather than the information from 
the data sheet because the expression of PD-L2 was  heterogeneous 
in the same tumor nest.
For immunocytochemistry, cells cultured on coverslips were 
fixed with 4% paraformaldehyde and permeabilized by incubation 
with 0.2% Triton X-100 in PBS. Following incubation with the pri-
mary antibodies, the antibody bindings were visualized using anti–
mouse immunoglobulin G conjugated with Alexa Fluor 488 (1:200; 
Molecular Probes). Immunostained cells were then counterstained 
with DAPI (Vector Laboratories).
2.11 | Collection of exfoliative cells and 
papanicolaou staining
Oral smears were taken from buccal sites in patients with OSCC 
using the EndoCervix-Brush (Rover Medical Devices, KV Oss). 
Intraoperative cytology was performed on patients diagnosed with 
OSCC before surgery. Only specimens that were diagnosed as OSCC 
from postoperative pathology were used. In addition, the Japanese 
Society of Oral Surgery Oral Cancer Practice Guidelines, 2019 
edition (draft), was used to provide guidelines for the diagnosis of 
OSCC. The brushes were immersed and washed in CytoRich Red 
Fluid to scatter the cells in the solution. After centrifugation, cell pel-
lets were suspended in distilled water. Cell suspensions were refixed 
in 95% ethanol. Papanicolaou staining was used for cytopathology. 
The collected cells were stained using the same method as described 
for immunocytochemistry.
2.12 | Silencing and overexpressing of programmed 
cell death ligands in HSC-2
Silencer siRNA for PDCD1LG2 (B7DC) gene, 5′-CCUAAGGAACUG 
UACAUAAtt-3′, was purchased from Thermo Fisher Scientific. After 
culturing with 1 × 105 cells/mL in six-well plates for 1 day, the cells 
were transfected with 40 nmol/L siRNA using the Lipofectamine 
RNAi MAX Reagent (Thermo Fisher Scientific) in accordance with 
the manufacturer’s protocol. For the control transfection, Silencer 
Select Negative Control No. 1 siRNA (Thermo Fisher Scientific) was 
used.
The nucleotide coding sequences of human PD-L2 were ampli-
fied by PCR using the human HSC-2 cDNA as a template and the 
following PD-L2 specific primers: sense 5′ primer AAC ATG ATC 
TTC CTC CTG CTA ATG T and antisense 3′ primer TCA GAT AGC 
ACT GTT CAC TTC CC. The plasmid was linearized by digestion 
with KpnI and XbaI, and the amplified cDNA (822bp) was inserted 
into p3xFlag-CMV-7.1 (Sigma-Aldrich) using DNA ligase. The nu-
cleotide sequences of the PCR-amplified cDNA were confirmed by 
DNA sequencing. The plasmids were transfected into the cells using 
Lipofectamine 3000 (Thermo Fisher Scientific). We used western 
blot analysis to validate the expression level of PD-L2 in transfected 
HSC-2 cells with expressing plasmid or siRNA.
2.13 | Statistical analyses
Data are expressed as the mean ± standard error of the mean (SEM). 
Differences were analyzed by one-way analysis of variance, χ2 test 
and Scheffe’s multiple comparison test. P-values < 0.05 were con-
sidered significant.
3  | RESULTS
3.1 | Upregulation of programmed cell death ligand 
2 and ABCG2 in cisplatin-resistant HSC-2 cells
To clarify the resistance of HSC-2 cells to cisplatin, we first exam-
ined the effect of cisplatin on cell viability using the CCK assay 
(Figure 1A). HSC-2 cells without cisplatin dramatically proliferated 
in a time-dependent manner. However, after cisplatin treatment, the 
proliferation of HSC-2 cells was suppressed in a dose-dependent 
manner. The number of viable cells with cisplatin remained con-
stant or was slightly decreased at cisplatin concentrations of 2 to 
5 μmol/L. These HSC-2 cells that survived with cisplatin treatment 
were considered a subset of cisplatin-resistant HSC-2 cells.
To clarify whether cisplatin-induced PD-L2 expression in OSCC, 
we examined the effect of cisplatin (2 μmol/L) on PD-L2 gene expres-
sion using quantitative RT-PCR (Figure 1B). Cisplatin treatment up-
regulated the gene expression of PD-L2, ALDH1, a stem cell marker, 
and the ABCG2 gene, which is a drug efflux ATP-binding cassette 
(ABC) transporter, in a time-dependent manner. This upregulated 
expression reached a peak level at 24 hours after cisplatin treatment.
Subsets of anti–tumor drug-resistant cells have been reported 
to depend on drug efflux ABC transporters.22,23 ABCG2 is an ABC 
transporter that is a major contributor in cancer stem cells.24,25 In 
addition, the activity of aldehyde dehydrogenases (ALDH), such as 
ALDH1, has been reported to define cancer stem cell populations in 
many cancer types and may act as a common marker for both normal 
and malignant stem cell populations.26,27
The increase in the cell surface expression of PD-L2 in cells 
treated with cisplatin was further confirmed using flow cytometry 
analysis, indicating the upregulation of PD-L2 in cisplatin-resistant 
HSC-2 cells compared with the control (without cisplatin treatment; 
Figure 1C). Similar results were obtained using immunofluores-
cence staining, which showed that cisplatin treatment for 24 hours 
upregulated the expression of PD-L2, as well as ABCG2, in HSC-2 
cells (Figure 1D). The cisplatin-induced PD-L2 expression was lo-
calized in both the cytoplasm and the membrane after separation 
of the cytoplasm and membrane fractions using western blot anal-
ysis (Figure 1E). Cisplatin treatment also upregulated the expres-
sion of PD-L2 and ABCG2 in HSC-3 cells, the other OSCC cell line 
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(Figure 2S). Treatment with hydrogen peroxide (500 μmol/L), a reac-
tive oxidant species, also upregulated PD-L2 expression, together 
with ABCG2, and peaked 24 hours after treatment. In contrast, pre-
treatment of N-acetylcysteine (10 μmol/L), an antioxidant drug, par-
tially suppressed the cisplatin-upregulated PD-L2 expression.
3.2 | Signal transducers and activator of 
transcription 1/3 involvement in programmed cell 
death ligand 2 upregulation
A number of cytokines, including INF-γ, GM-CSF, IL-4 and TNF-α, 
have been reported to induce PD-L expression.28 The reactions of 
these cytokines have been reported to be partially mediated by 
the transcription factors STAT and IRF. It has also been reported 
that INF-γ induced PD-L1 expression is mediated by JAK/STAT 
pathways.29,30 To elucidate which transcription factors mediate 
cisplatin-induced PD-L2 expression, we next examined the effect 
of cisplatin on the activation of various kinases and transcriptional 
factors. Cisplatin treatment gradually induced STAT1 and STAT3 
gene expression in HSC-2 cells in a time-dependent manner com-
pared with the control (Figure 2A). Accordingly, cisplatin treatment 
upregulated the expression of the STAT1 and STAT3 proteins for 
24 hours (Figure 2B). The cisplatin treatment also dominantly up-
regulated STAT3 expression and this protein remained phospho-
rylated more than 1 hour after treatment compared with STAT1 
F I G U R E  1   Cisplatin-induced programmed death-ligand 2 (PD-L2) expression in anti–tumor drug-resistant HSC-2 cells. A, HSC-2 cells 
were incubated with various concentrations of cisplatin for 0-72 h. After cisplatin treatment, the number of viable cells was determined by 
the CCK8 assay. B, Expression of PD-L2, ABCG2 and ALDH1 genes in HSC-2 cells with or without cisplatin treatment (2 μmol/L). Samples 
were analyzed by RT-PCR. Data shown are the means from seven culture wells (mean ± SEM). * and ** indicate P < 0.05 and P < 0.01, 
respectively, vs control (0 h). C, Cells were treated without (control) or with cisplatin (2 μmol/L). Flow cytometry analysis used 20 000 
cells/each sample. Mouse IgG-PE (isotype) was used as a negative control. D, The immunocytochemistry expression of PD-L2 and ABCG2 
in cisplatin-treated HSC-2 cells was also confirmed. Scale bar = 50 μm. E, Western blotting was conducted using targeted and β-actin 
antibodies in membrane and cytoplasm fractions separated from HSC-2 cells treated with cisplatin for 24 h. Similar results were obtained 
from three independent experiments
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(Figure 2C). However, cisplatin treatment had little effect on the 
activation of other kinases, including AMPK, PTEN and PI3K 
(Figure S2).
Cisplatin treatment in the presence of fludarabine (10 μmol/L), 
a STAT1 inhibitor, or cryptotanshinone (10 μmol/L), a STAT3 inhibi-
tor, decreased the relative number of PD-L2-positive cells compared 
with cisplatin alone (Figure 2D). The combination of cisplatin with 
either the STAT1 or STAT3 inhibitor also suppressed the phosphory-
lation of STAT1/3, particularly that of p-STAT1.
3.3 | The relationship between programmed cell 
death ligand 2 expression and malignancy in oral 
squamous cell carcinoma 
Some studies have reported that PD-L expression is associated 
with malignant potential, resulting in a decrease in overall sur-
vival in various cancers.31,32 To further examine this issue, HSC-2 
cells were separated into PD-L2-positive and PD-L2-negative 
cells using fluorescence-activated cell sorting, in which PD-L2 
expression was confirmed by western blot analysis (Figure 3A). 
To clarify whether PD-L2 expression in HSC-2 cells was associ-
ated with malignant behavior, we examined the effect of PD-L2 
expression on cellular proliferation using the colony assay 
(Figure 3B). There was no difference in proliferation activity be-
tween PD-L2-positive and PD-L2-negative cells on days 10 and 
13. Next, we examined the tumor invasion ability, using transwell 
assays, and cellular transforming ability, using agar floating cul-
ture assays, in PD-L2-overexpressing and PD-L2-silencing cells. 
The number of cells that passed from the upper to the lower 
chamber through the collagen gel-coated transwell increased 
in a time-dependent manner (Figure 3C). In particular, a greater 
number of PD-L2-overexpressing or PD-L2-positive cells passed 
through the collagen gel compared with PD-L2-negative cells 
over a 48-hour period. In contrast, the number of invading cells 
decreased with the silencing of PD-L2 in collected PD-L2 posi-
tive cells. Furthermore, the number of HSC-2 cell colonies in the 
agar floating culture of PD-L2-overexpressing or PD-L2-positive 
cells was significantly greater than that observed for PD-L2-
negative cells (Figure 3D).
F I G U R E  2   Cisplatin-induced programmed death-ligand 2 (PD-L2) expression is mediated by signal transducers and activator of 
transcription 1/3 (STAT1/3) activation in HSC-2 cells. Expression of PD-L2, STAT1 and STAT3 in HSC-2 cells with or without cisplatin 
treatment (2 μmol/L) for 0-48 h using quantitative RT-PCR analysis (A) and western blot analysis (B). Bar graphs show the mean from seven 
culture wells (mean ± SEM). * and ** indicate P < 0.05 and P < 0.01, respectively, vs control (0 h). The effect of a STAT1 or STAT3 inhibitor 
on PD-L2 expression (C) and the activation of STAT1/3 phosphorylation (D). HSC-2 cells were incubated with cisplatin in the presence or 
absence of a STAT1 or STAT3 inhibitor for 24 h. Similar results were obtained from three independent experiments
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3.4 | Oral squamous cell carcinoma patients 
expressing programmed cell death ligand 2
To clarify whether PD-L2 is expressed in the tumor tissues of OSCC 
patients, we next examined PD-L2 expression in OSCC cells from 
patients using cytological methods and commercial paraffin tissue 
microarrays in human oral cancers (Figure 4A,B) in conjunction with 
immunochemical staining. Using exfoliative cytological methods, we 
separated the cells derived from OSCC patients. These cells were 
severely atypical squamous cells with high nuclear-cytoplasmic ratio, 
hyperchromatic nuclei and nuclear pleomorphism, suggesting OSCC 
as determined by papanicolaou staining. In addition, PD-L2 expres-
sion in these cells was localized around the cellular membrane as 
determined by immunocytofluorescence. PD-L2 expression was 
also observed in OSCC tissues derived from the tongue and gingiva 
of SCC patients, but not in normal tissues, in oral tissue microarray 
preparation. The rate of PD-L2 positivity was 67.7% (113/ 167 in 
total tissues) and was dominant in males (P < 0.03) in the relationship 
between clinicopathological characteristics and PD-L2 expression 
(Table S1). Furthermore, the intensity of PD-L2 expression was sig-
nificantly and positively correlated to the differentiation degree and 
invasive pattern (Table 1).
4  | DISCUSSION
Cisplatin-based neoadjuvant chemotherapy in cancer patients is 
known to induce PD-L1-positive cells in tumors and immunocytes. 
In this study, we found that cisplatin treatment upregulated PD-L2 
and ABCG2 expression. ABCG2 is a drug efflux transporter in oral 
squamous tumors. Our findings indicate that the anti–tumor drug 
resistance in OSCC may be associated with PD-L2 expression during 
chemotherapy.
It has recently been reported that cisplatin induces PD-L1 ex-
pression in bladder cancer and non–small cell lung cancer cell 
lines.20,21 In bladder cancer, cisplatin treatment serves to upregu-
late PD-L1 expression via the ERK signaling pathway, followed by 
AP-1. In addition, PD-L1 is variably expressed in the cytoplasm 
F I G U R E  3   The invasion and transformation ability of cisplatin-induced programmed death-ligand 2 (PD-L2)-positive cells. A, Cells were 
treated with cisplatin (2 μmol/L), followed by separation into PD-L2-positive and PD-L2-negative cell populations using fluorescence-
activated cell sorting. B, Differences between the PD-L2-positive or expressing and PD-L2-negative or silencing cells in terms of 
proliferation (B) as determined by the colony formation assay, invasion (C) by the transwell assay and transformation (D) by the floating agar 
culture assay. Bar graphs show the mean from seven culture wells (mean ± SEM). * and ** indicate P < 0.05 and P < 0.01 vs mock cells at 48 h 
(C) or PD-L2 (+) cells (D)
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and cell membrane in ovarian cancer cells.33 However, the mech-
anism of cisplatin-induced PD-L1 expression in these tumor cells 
remains largely unclear. In the current study, our results indicated 
that cisplatin treatment upregulated PD-L2 expression in both the 
membrane and cytoplasm fractions of OSCC via STAT1/3 activa-
tion. PD-L1 expression has been reported to be associated with the 
FI G U R E 4 Programmed death-ligand 2 (PD-L2) expression in squamous cells isolated from oral squamous cell carcinoma (OSCC) patients and 
oral tissue microarray. A, Representative images of the exfoliative epithelium isolated from an OSCC patient and stained with papanicolaou and 
immunofluorescence. Scale bar = 50 μm. B, Immunohistochemical staining for PD-L2 in various oral tissue samples by microarray. Scale bar = 50 μm
TA B L E  1   Correlation between programmed death-ligand 2 (PD-L2) expression and histological grading and invasive pattern
Factors
PD-L2 negative PD-L2 positive
n (%) (exp., st. resid.) Low Intermediate High
P-value(n = 46) (n = 80) (n = 22) (n = 5)
Differentiation degree
Grade I 36 (78.3) 38 (47.5) 1 (4.5) 0 (0) 0.0001
(22.549, 4.744)** (39.216, −0.394) (10.784, −4.510)** (2.451, −2.229)*
Grade II 10 (21.7) 37 (46.5) 13 (54.1) 3 (60.0)
(18.941, −3.203)** (32.941, 1.335) (9.059, 1.845) (2.059, 0.870)
Grade III 0 (0) 5 (6.2) 8 (36.4) 2 (40.0)
(4.510, −2.674)** (7.843, −1.548) (2.157, 4.527)** (0.490, 2.309)*
Invasive pattern
Expansive type 
(YK-1, −2)
30 (65.2) 10 (12.5) 0 (0) 0 (0) 0.000001
(12.026, 7.212)** (20.915, −4.021)** (5.752, −3.016)** (1.307, −1.353)
Intermediate 
type (YK-3)
16 (34.8) 63 (78.8) 15 (68.2) 3 (60.0)
(29.163, −4.818)** (50.719, 4.127)** (13.948, 0.503) (3.170, −0.160)
Invasive type 
(YK-4C, −4D)
0 (0) 7 (8.7) 7 (31.8) 2 (40.0)
(4.801, −2.772)** (8.366, −0.723) (2.301, 3.538)** (0.523, 2.195)*
exp., expected value; st.resid., standardized residual.
*P < 0.05, **P < 0.01. 
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epithelial-mesenchymal transition (EMT) observed during metas-
tasis in lung and breast cancer, and esophageal SCC via ZEB1 ac-
tivation.34-36 Moreover, cisplatin treatment has been reported to 
increase intracellular ROS levels37,38 and treatment with antioxidants 
has been shown to ameliorate the toxic effects of cisplatin.39,40 ROS 
themselves are known to induce the EMT in normal and SCC cells.41-
43 Indeed, we found that hydrogen peroxide also upregulated PD-L2 
expression in HSC-2 cells, whereas treatment of the antioxidant drug 
partially suppressed the cisplatin-upregulated PD-L2 expression in 
the present experiments. These findings, along with the present 
data, suggest that cisplatin-induced PD-L2 expression in OSCC is 
caused by the EMT via ROS induction.
Numerous reports have indicated that PD-L expression in car-
cinogenesis is regulated by various intracellular signaling pathways. 
Indeed, the upregulation of PD-L1 is believed to be driven by the 
activation of constitutive oncogenic signaling pathways, such as 
MAPK and PI3K-AKT, as well as transcriptional factors, including 
HIF-1, STAT3 and NF-κB.44,45 Furthermore, upregulation of PD-L1 
depends on IRF1 and STAT1 binding to their promoter, while PD-L2 
upregulation appears to depend on the IRF1 and STAT1/3 binding 
promoter.28,29
In the present study, the presence of a STAT1 or STAT3 inhibitor 
partially suppressed the cisplatin-induced PD-L2 expression, sug-
gesting that cisplatin may mediate STAT1/3 binding at the promoter 
sites of PDCD1LG2.
In general, cancers are regarded as heterogeneous tissues involv-
ing a variety of cells that originate from a unique and rare subset of 
cells that possess the ability to self-renew and have the potential to 
differentiate into multiple cell lineages.46 Cancer stem cells, a subset 
of cancer cells with stem-like properties, are responsible for tumor 
initiation, progression, recurrence and metastasis, as well as the cel-
lular resistance to chemotherapy and radiotherapy.47-49 Cancer cells 
that are resistant to anti–tumor drugs have been reported to depend 
on ABC transporter activity.22,23 ABCG2 is a member of the ABC 
transporter family and is a major factor in the drug resistance ob-
served in cancer stem cells. Indeed, ABCG2 contribute to multidrug 
resistance to chemotherapy in several types of cancer.24,25 In con-
trast, Abcg2 transporter gene knockout mice have been shown to 
be particularly sensitive to chemotherapeutic agents, indicating that 
ABCG2 is critical for maintaining drug-resistant stem cells.50
In this study, we found that cisplatin treatment increased the 
percentage of ABCG2-positive cells, so that >50% of the HSC-2 cells 
were positive for ABCG2. This increase likely contributes to the stem 
cell properties of cells expressing ABCG2 and ALDH1 in OSCC, sug-
gesting a possible mechanism for the high metastasis observed in 
anti–tumor drug-resistant cells. Indeed, PD-L2-positive or PD-L2-
overexpressing HSC-2 cells in the current study had increased inva-
sion and transformation ability. Thus, the subset of cancer stem cells 
with anti–tumor drug resistance among OSCC may become more 
malignant with increased invasion and transformation associated 
with upregulation of PD-L2 expression.
Previous studies have shown that PD-L1 and PD-L2 have dif-
ferent prognostic roles in various tumors, suggesting that different 
tumor subsets exist, including in cancer stem cells.51,52 Although 
PD-L1 is known to be expressed in oral tissues derived from the 
tongue and salivary glands of cancer patients,53-55 the significance 
of PD-L2 has not yet been systematically evaluated in OSCC. Thus, 
we analyzed cisplatin-induced PD-L2 expression in an OSCC cell line 
and in OSCC cytology and tissue samples derived from patients with 
OSCC. We found that PD-L2 expression was observed in OSCC cells 
derived from the tongue and gingiva of patients but not in normal 
tissues.
In line with experimental findings, the intensity of PD-L2 ex-
pression was positively correlated with more malignant morpho-
logical features, suggesting that poorly differentiated and invasive 
OSCC cells take advantage of expressing PD-L2 to evade immune 
surveillance. In addition, at least one of two PD-L was detected in 
the OSCC cells of four available tissue microarray spots from lymph 
node metastasis, implying that the two molecules may compensate 
each other to metastasize to lymph nodes (Figure S3).
In conclusion, cisplatin treatment upregulated PD-L2 and ABCG2 
expression in OSCC cell lines via STAT1/3 activation . In addition, 
upregulated PD-L2-positive cells had greater invasion and transfor-
mation ability and PD-L2 expression was observed in epithelial cells 
derived from OSCC patients. Collectively, our novel findings suggest 
that cisplatin-induced PD-L2 expression in OSCC cells may be a crit-
ical factor in the prognosis of advanced OSCC patients.
ACKNOWLEDG MENTS
This work was supported by Grants-in-Aid for Scientific Research 
from the Ministry of Education, Culture, Sports, Science and 
Technology of Japan (15K11062 to HK) and the Private University 
Research Branding Project at Fukuoka Dental College. The authors 
would like to thank Enago (www.enago.jp) for the English language 
review.
CONFLIC T OF INTERE S T
The authors have no conflicts of interest.
ORCID
Hiroshi Kajiya  https://orcid.org/0000-0003-3275-3632 
R E FE R E N C E S
 1. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 im-
munoinhibitory receptor by a novel B7 family member leads 
to negative regulation of lymphocyte activation. J Exp Med. 
2000;192:1027-1034.
 2. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand 
for PD-1 and inhibits T cell activation. Nat Immunol. 2001;3:261-268.
 3. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman 
AH. Proatherogenic immune responses are regulated by the PD-1/
PD-L pathway in mice. J Clin Invest. 2007;117:2974-2982.
 4.  Riella LV,  Watanabe T,  Sage PT, et al. Essential role of PDL1 ex-
pression on nonhematopoietic donor cells in acquired tolerance to 
vascularized cardiac allografts. Am J Transplant. 2011;11:832-840.
 5. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 
promotes T-cell apoptosis: a potential mechanism of immune eva-
sion. Nat Med. 2002;8:793-800.
10  |     SUDO et al.
 6. Ichikawa M, Chen L. Role of B7–H1 and B7–H4 molecules in 
down-regulating effector phase of T-cell immunity: novel cancer 
escaping mechanisms. Front Biosci. 2005;10:2856-2860.
 7. Brown JA, Dorfman DM, Ma F-R, et al. Blockade of programmed 
death-1 ligands on dendritic cells enhances T cell activation and cy-
tokine production. J Immunol. 2003;170:1257-1266.
 8. Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 
and its engagement with PD-L2 promotes respiratory tolerance. J 
Exp Med. 2014;211:943-959.
 9. Jie H-B, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T 
cells upregulate immunosuppressive molecules in head and neck 
cancer patients. Br J Cancer. 2013;109:2629-2635.
 10. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrat-
ing immunity’s roles in cancer suppression and promotion. Science. 
2011;331:1565-1570.
 11. Kim M-Y, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological 
analysis of PD-L1 and PD-L2 expression in pulmonary squamous 
cell carcinoma: comparison with tumor-infiltrating T cells and the 
status of oncogenic drivers. Lung Cancer. 2015;1:24-33.
 12. Kano M, Hayano K, Hayashi H, et al. Survival benefit of neoadju-
vant chemotherapy with S-1 plus docetaxel for locally advanced 
gastric cancer: a propensity score-matched analysis. Ann Surg 
Oncol. 2019;6:1805-1813.
 13. Yearley JH, Gibson C, Yu NI, et al. PD-L2 expression in human tu-
mors: relevance to anti–PD-1 therapy in cancer. Clin Cancer Res. 
2017;23:3158-3167.
 14. Youngnak P, Kozono Y, Kozono H, et al. Differential binding proper-
ties of B7–H1 and B7-DC to programmed death-1. Biochem Biophys 
Res Commun. 2003;307:672-677.
 15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global 
cancer statistics. CA Cancer J Clin. 2011;61:69-90.
 16. Herbst RS, Sznol M. Diminished but not dead: chemotherapy for 
the treatment of NSCLC. Lancet Oncol. 2016;17:1464-1465.
 17. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab 
versus chemotherapy for PD-L1-positive non–small-cell lung can-
cer. N Engl J Med. 2016;375:1823-1833.
 18. Schwartz GJ, Mehta RH, Wenig BL, Shaligram C, Portugal LG. 
Salvage treatment for recurrent squamous cell carcinoma of the 
oral cavity. Head Neck. 2000;22:34-41.
 19. Shin J, Kim G, Lee JW, et al. Identification of ganglioside GM2 acti-
vator playing a role in cancer cell migration through proteomic anal-
ysis of breast cancer secretomes. Cancer Sci. 2016;1107:828-835.
 20. Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expres-
sion and optimizes immune check-point blockade in non–small cell 
lung cancer. Cancer Lett. 2019;464:5-14.
 21. Tsai TF, Lin JF, Lin YC, et al. Cisplatin contributes to programmed 
death-ligand 1 (PD-L1) expression in bladder cancer through 
ERK1/2-AP-1 signaling pathway. Biosci Rep. 2019;39.
 22. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 trans-
porter is an efficient Hoechst 33342 efflux pump and is preferen-
tially expressed by immature human hematopoietic progenitors. 
Blood. 2002;99:507-512.
 23. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/
ABCG2 is expressed in a wide variety of stem cells and is a mo-
lecular determinant of the side-population phenotype. Nat Med. 
2001;7:1028-1034.
 24. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer 
cell lines and tumors is enriched with stem-like cancer cells. Cancer 
Res. 2007;67:4827-4833.
 25. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in 
multidrug resistance. Int J Biochem Mol Biol. 2012;3:1-27.
 26. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of 
normal and malignant human mammary stem cells and a predictor 
of poor clinical outcome. Cell Stem Cell. 2007;1:555-567.
 27. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr 
Stem Cell Res Ther. 2008;3:237-246.
 28. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor sig-
naling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 
2017;19:1189-1201.
 29. Horlad H, Ma C, Yano H, et al. An IL-27/Stat3 axis induces expres-
sion of programmed cell death 1 ligands (PD-L1/2) on infiltrating 
macrophages in lymphoma. Cancer Sci. 2016;107:1696-1704.
 30. Lin C, Cao W, Ren Z, et al. GDNF secreted by nerves enhances 
PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. 
Oncoimmunology. 2017;6:e1353860.
 31. Feng M, Xiong G, Cao Z, et al. PD-1/PD-L1 and immunotherapy for 
pancreatic cancer. Cancer Lett. 2017;407:57-65.
 32. Prat A, Navarro A, Paré L, et al. Immune-related gene expression 
profiling after PD-1 blockade in non–small cell lung carcinoma, head 
and neck squamous cell carcinoma, and melanoma. Cancer Res. 
2017;77:3540-3550.
 33. Qu QX, Xie F, Huang Q, et al. Membranous and cytoplasmic ex-
pression of PD-L1 in ovarian cancer cells. Cell Physiol Biochem. 
2017;43:1893-1906.
 34. Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand 
PD-L1 is upregulated in EMT-activated human breast cancer cells 
by a mechanism involving ZEB-1 and miR-200. Oncoimmunology. 
2017;6:e1263412.
 35. Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 
1 expression at tumor invasive front is associated with epitheli-
al-mesenchymal transition and poor prognosis in esophageal squa-
mous cell carcinoma. Cancer Sci. 2017;108:1119-1127.
 36. Raimondi C, Carpino G, Nicolazzo C, et al. PD-L1 and epitheli-
al-mesenchymal transition in circulating tumor cells from non–small 
cell lung cancer patients: a molecular shield to evade immune sys-
tem? Oncoimmunology. 2017;6:e1315488.
 37. Jiang Y, Guo C, Vasko MR, Kelley MR. Implications of apurinic/apy-
rimidinic endonuclease in reactive oxygen signaling response after 
cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 
2008;68:6425-6434.
 38. Santos NA, Catão CS, Martins NM, Curti C, Bianchi MLP, Santos 
AC. Cisplatin-induced nephrotoxicity is associated with oxida-
tive stress, redox state unbalance, impairment of energetic me-
tabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 
2007;81:495-504.
 39.  El-Beshbishy HA,  Bahashwan SA,  Aly HAA, Fakher HA. Abrogation 
of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid 
through ameliorating oxidative stress and enhancing gene expres-
sion of antioxidant enzymes. Eur J Pharmacol. 2011;668:278-284.
 40. Santos NA, Bezerra CS, Martins NM, et al. Hydroxyl radical scav-
enger ameliorates cisplatin-induced nephrotoxicity by preventing 
oxidative stress, redox state unbalance, impairment of energetic 
metabolism and apoptosis in rat kidney mitochondria. Cancer 
Chemother Pharmacol. 2008;61:145-155.
 41. Fukawa T, Kajiya H, Ozeki S, Ikebe T, Okabe K. Reactive oxygen 
species stimulates epithelial mesenchymal transition in normal 
human epidermal keratinocytes via TGF-beta secretion. Exp Cell 
Res. 2012;318:1926-1932.
 42. Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expres-
sion in a high-grade invasive human oral squamous cell carcinoma 
microenvironment. Int J Oncol. 2017;50:41-48.
 43. Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in 
TGF-beta1-induced mitogen-activated protein kinase activation 
and epithelial-mesenchymal transition in renal tubular epithelial 
cells. J Am Soc Nephrol. 2005;16:667-675.
 44. Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K 
pathways on PD-L1 expression in melanoma. Clin Cancer Res. 
2014;20:3446-3457.
     |  11SUDO et al.
 45. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role 
of pro-survival signalling in cancer. Ann Oncol. 2016;27:409-416.
 46. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: ac-
cumulating evidence and unresolved questions. Nat Rev Cancer. 
2008;8:755-768.
 47. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly puri-
fied CD44+ prostate cancer cells from xenograft human tumors are 
enriched in tumorigenic and metastatic progenitor cells. Oncogene. 
2006;25:1696-1708.
 48. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain 
tumour initiating cells. Nature. 2004;432:396-401.
 49. Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tu-
mors: an overview and new approaches for their isolation and char-
acterization. FASEB J. 2013;27:13-24.
 50. Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of 
gene expression in human CD34(+) stem/progenitor cells. Proc Natl 
Acad Sci USA. 2001;98:13966-13971.
 51. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of 
programmed death-1 ligand-1 and programmed death-1 li-
gand-2 expression in human esophageal cancer. Clin Cancer Res. 
2005;11:2947-2953.
 52. Shin S-J, Jeon YK, Kim P-J, et al. Clinicopathologic analysis of PD-L1 
and PD-L2 expression in renal cell carcinoma: association with on-
cogenic proteins status. Ann Surg Oncol. 2016;23:694-702.
 53. Nakano T, Takizawa K, Uezato A, Taguchi K, Toh S, Masuda M. 
Prognostic value of programed death ligand-1 and ligand-2 co–ex-
pression in salivary gland carcinomas. Oral Oncol. 2019;90:30-37.
 54. Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification 
and PD-L1 protein expression are common events in squamous cell 
carcinoma of the oral cavity. Oncotarget. 2016;7:12024-12034.
 55. Yoshida S, Nagatsuka H, Nakano K, et al. Significance of 
PD-L1 expression in tongue cancer development. Int J Med Sci. 
2018;15:1723-1730.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.    
How to cite this article: Sudo S, Kajiya H, Okano S, et al. 
Cisplatin-induced programmed cell death ligand-2 expression 
is associated with metastasis ability in oral squamous cell 
carcinoma. Cancer Sci. 2020;00:1–11. https ://doi.
org/10.1111/cas.14336 
